The massive share issuance (likely >10x current outstanding) will severely dilute existing common and warrant holders. Monitor stockholder vote and regulatory milestones for IBC101; the related-party conflict may increase deal risk. Price action likely volatile on dilution fears vs. pipeline promise.
Price Chart
Executive Summary
Liminatus Pharma entered a merger agreement to acquire InnocsAI LLC, a private CAR-T therapy company, for 1.6 billion shares of common stock at $0.20 per share ($320 million implied value) plus contingent value rights. The deal includes a related-party transaction as CEO Chris Kim controls a member of InnocsAI. The target's lead candidate IBC101 has Phase 1/2a authorization in Korea. The massive dilution and early-stage pipeline create significant uncertainty.
Key Financial Metrics
Key Facts
- 1.6 billion shares issued at $0.20 per share to InnocsAI members
- Contingent value rights representing 20% of future net proceeds from asset sales
- IBC101 (CD19xCD22 CAR-T) has Phase 1/2a authorization in Korea for DLBCL
- Chris Kim, CEO of Liminatus, is also CEO of Valetudo Therapeutics, a member of InnocsAI (related-party transaction)
- Closing conditions include stockholder approval and absence of injunctions; deal must close by December 31, 2026
Financial Impact
Implied deal value of $320 million based on 1.6B shares at $0.20/share; additional contingent value rights not quantified
Risk Factors
- Extreme dilution from 1.6B new shares could crush current equity value
- Early-stage CAR-T pipeline faces high clinical and regulatory risk
- Related-party transaction may lead to shareholder opposition or legal challenges
- No revenue or financials disclosed for either party; deal may not close by year-end
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-064585 |
| Document: tm2615228d1_8k.htm | 0001104659-26-064585 |
| Document: 0001104659-26-064585-index-headers.html | 0001104659-26-064585 |
| Document: 0001104659-26-064585-index.html | 0001104659-26-064585 |
| Document: 0001104659-26-064585.txt | 0001104659-26-064585 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | 8-K | $0.0600 $0.0600 | · 0.00% | ▲ +1.37% | — |
May 20, 2026 22w ago | 8-K | $0.0600 $0.0600 | · 0.00% | ▼ −0.33% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers